Side by side
Compare compounds
Add up to three compounds with the compare button on any library card or compound page.
Swipe the table sideways to see every compound.
| Attribute |  |
|---|---|
| Category | Metabolic |
| Evidence grade | A Human trial evidence |
| Regulatory status | FDA-approved |
| Human amounts | FDA labelDosing reference Study durations |
| Format | |
| Type | Single compound |
| Molecular formula | C48H48F2N10O5 |
| Molecular weight | 883 g/mol |
| CAS number | 2212020-52-3 |
| Sequence | Not listed |
| References | 9 |
| Summary | Orforglipron is an oral, once-daily small-molecule (non-peptide) GLP-1 receptor agonist that the FDA approved in April 2026 as Foundayo for chronic weight management in adults with obesity or overweight with a weight-related condition. |